1983级 化学工程系
Class 1983 Department of Chemical Engineering
北京大清生物技术有限公司 董事长
Director, Beijing Datsing Bio-Tech Co.,Ltd.
北京大清创业投资有限公司 总经理
CEO，Beijing Datsing Venture Capital Co.,Ltd.
清华大学新百年发展基金发起人，监事
Charter Member and Supervisor of New Century Development Fund Of Tsinghua University
李次会先生在生物医药领域有25年工作经历，先后从事研发、生产技术管理、项目管理、营销管理、医药企业管理、医药行业投资等多项工作。对国内外医药和生物技术前沿有深刻理解和洞察力，熟悉国家生物医药领域的政策和法律法规，熟悉GMP、ISO9000等各种技术规范。尤其是作为组织工程和再生医学领域的先行者，对生物医学材料和组织工程产品的产业化具有丰富的开发和管理经验。先后参与多项重大项目的研究,领导经营团队获得国家新药证书、医疗器械注册证书10余个，其中一个项目获得了北京市科技进步一等奖、中华医学科技奖三等奖。目前担任多个专业学会理事、杂志编委，以及行业协会、联盟理事等。
2005年创业以来，在经营医药实业同时开展生物医药相关行业的高新技术项目投资活动，利用企业自身资本先后投资11个，均取得较好的项目回报或良好发展，得到生物医药领域和创投行业的肯定。
Mr. Li Cihui has more than 25 years work experience in the field of bio-medicine, has engaged in R & D, production and technology management, project management, marketing management, management of pharmaceutical companies, pharmaceutical industry investment and more. He has a deep understanding of and insight into the forefront of the domestic and international pharmaceutical and biotechnology, familiar with GMP, ISO9000 and ISO13485 sterile medical devices and other technical specifications, familiar with the policies and regulations of the national biomedical field.Especially as a pioneer in the field of tissue engineering and regenerative medicine,he has wealth experience in the industrialization of biomedical materials and tissue engineering products and has been involved in a number of major research projects, published more than 10 papers at home and abroad, leading his management team, they had got the national drug certificate and registration certificate of medical devices more than 10, one of the items obtained Beijing Science and Technology progress Award, Chinese Medical Science and Technology Award third prize.Currently, he also works as a association, magazine editorial, and union governing in the professional field.
Since 2005,he carried out a high-tech project investment activities about bio-pharmaceutical industry,had invested about 11 and achieved a good return on the project and good development, affirmed by the biomedical field and the venture capital industry.
